ERBB2 and breast carcinoma: The study shows that anti-HER2 vaccination using the M13 bacteriophage platform induces a significant anti-HER2 antibody response and controls tumor growth in a breast cancer preclinical model, proving that anti-HER2 phage-based vaccines are a safe and successful immunotherapeutic strategy for HER2+ breast cancer patients (Figure 6B) [249].